CHRS logo

CHRS Coherus Oncology, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$0.37
-0.02 (-4.47%)

Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for…

Market Cap: $57.15Mwww.coherus.com

Price

No data yet.

Social Signal Score

48
5d
57
1 mentions
—
30d
44
11 mentions
—
60d
45
12 mentions
—
90d
45
14 mentions
—
news: 14

Analyst Ratings

17 analysts
Buyconsensus
Strong Buy 0Buy 14Hold 3Sell 0Strong Sell 0
Avg price target$6.02+1527.9%
Low $1.05Median $6High $11
Current Consensus

Revenue

$14.27M+1591.23%
$0.00$45.22M$90.45M$135.67M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-1.54
$-1.74–$-1.44
1 analysts
FY2026
$-0.89
$-0.92–$-0.86
2 analysts
FY2027
$-0.66
$-0.74–$-0.59
2 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Dennis Lanfear
Sector
Healthcare
Industry
Biotechnology
Employees
145
Beta
1.03
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
-14.13
www.coherus.com